307 related articles for article (PubMed ID: 35158962)
1. Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors.
Grumetti L; Lombardi R; Iannelli F; Pucci B; Avallone A; Di Gennaro E; Budillon A
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158962
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.
Fazzone W; Wilson PM; Labonte MJ; Lenz HJ; Ladner RD
Int J Cancer; 2009 Jul; 125(2):463-73. PubMed ID: 19384949
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
Jenke R; Reßing N; Hansen FK; Aigner A; Büch T
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562653
[TBL] [Abstract][Full Text] [Related]
4. Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors.
Roca MS; Di Gennaro E; Budillon A
J Clin Med; 2019 Jun; 8(7):. PubMed ID: 31247937
[TBL] [Abstract][Full Text] [Related]
5. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects.
Singh A; Patel P; Patel VK; Jain DK; Veerasamy R; Sharma PC; Rajak H
Curr Cancer Drug Targets; 2017; 17(5):456-466. PubMed ID: 28067178
[TBL] [Abstract][Full Text] [Related]
7. BET inhibitors: a novel epigenetic approach.
Doroshow DB; Eder JP; LoRusso PM
Ann Oncol; 2017 Aug; 28(8):1776-1787. PubMed ID: 28838216
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
Gao S; Li X; Zang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
10. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors.
Tinari N; De Tursi M; Grassadonia A; Zilli M; Stuppia L; Iacobelli S; Natoli C
Curr Cancer Drug Targets; 2012 May; 12(4):439-52. PubMed ID: 22309455
[TBL] [Abstract][Full Text] [Related]
11. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
Huang Z; Zhou W; Li Y; Cao M; Wang T; Ma Y; Guo Q; Wang X; Zhang C; Zhang C; Shen W; Liu Y; Chen Y; Zheng J; Yang S; Fan Y; Xiang R
Theranostics; 2018; 8(18):4995-5011. PubMed ID: 30429882
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
[TBL] [Abstract][Full Text] [Related]
13. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
Bai Y; Ahmad D; Wang T; Cui G; Li W
Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
Feng W; Zhang B; Cai D; Zou X
Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
[TBL] [Abstract][Full Text] [Related]
15. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents.
Ververis K; Hiong A; Karagiannis TC; Licciardi PV
Biologics; 2013; 7():47-60. PubMed ID: 23459471
[TBL] [Abstract][Full Text] [Related]
17. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
18. Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Takai N; Kira N; Ishii T; Nishida M; Nasu K; Narahara H
Asian Pac J Cancer Prev; 2011; 12(3):575-80. PubMed ID: 21627347
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials.
Hontecillas-Prieto L; Flores-Campos R; Silver A; de Álava E; Hajji N; García-Domínguez DJ
Front Genet; 2020; 11():578011. PubMed ID: 33024443
[TBL] [Abstract][Full Text] [Related]
20. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
Hu WY; Xu L; Chen B; Ou S; Muzzarelli KM; Hu DP; Li Y; Yang Z; Vander Griend DJ; Prins GS; Qin Z
Prostate; 2019 Jul; 79(10):1166-1179. PubMed ID: 31135075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
